- Home
- BYFC vs ADAP Comparison
BYFC vs ADAP Comparison
Compare BYFC & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYFC
- ADAP
- Stock Information
- Founded
- BYFC 1946
- ADAP 2008
- Country
- BYFC United States
- ADAP United Kingdom
- Employees
- BYFC N/A
- ADAP 506
- Industry
- BYFC Savings Institutions
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- BYFC Finance
- ADAP Health Care
- Exchange
- BYFC Nasdaq
- ADAP Nasdaq
- Market Cap
- BYFC 63.8M
- ADAP 75.5M
- IPO Year
- BYFC 1996
- ADAP 2015
- Fundamental
- Price
- BYFC $6.55
- ADAP $0.29
- Analyst Decision
- BYFC
- ADAP Strong Buy
- Analyst Count
- BYFC 0
- ADAP 5
- Target Price
- BYFC N/A
- ADAP $1.83
- AVG Volume (30 Days)
- BYFC 11.2K
- ADAP 777.8K
- Earning Date
- BYFC 04-28-2025
- ADAP 05-13-2025
- Dividend Yield
- BYFC N/A
- ADAP N/A
- EPS Growth
- BYFC N/A
- ADAP N/A
- EPS
- BYFC N/A
- ADAP N/A
- Revenue
- BYFC $32,732,999.00
- ADAP $178,032,000.00
- Revenue This Year
- BYFC N/A
- ADAP N/A
- Revenue Next Year
- BYFC N/A
- ADAP $69.81
- P/E Ratio
- BYFC N/A
- ADAP N/A
- Revenue Growth
- BYFC N/A
- ADAP 195.34
- 52 Week Low
- BYFC $4.41
- ADAP $0.20
- 52 Week High
- BYFC $9.46
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- BYFC 48.41
- ADAP 51.38
- Support Level
- BYFC $6.36
- ADAP $0.30
- Resistance Level
- BYFC $7.10
- ADAP $0.32
- Average True Range (ATR)
- BYFC 0.36
- ADAP 0.02
- MACD
- BYFC 0.01
- ADAP 0.01
- Stochastic Oscillator
- BYFC 42.19
- ADAP 67.44
About BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.